Carvedilol Phosphate Capsule, Extended Release
Product Images NDC 0115-1248

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Carvedilol Phosphate (NDC 0115-1248). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Of New York Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Carvedilol Phosphate 1)

Chemical structure of carvedilol phosphate, as depicted in the image with a molecular formula indicating the presence of phosphoric acid and ethanol components.*

FDA Label Image

3 (Carvedilol Phosphate 10)

Label for Carvedilol Phosphate Extended-Release Capsules 40 mg by Amneal Pharmaceuticals of New York LLC. It indicates once-a-day dosing, packaging of 30 capsules, and highlights the extended-release capsule form. The label includes storage instructions, warnings, manufacturer and distributor details, and a barcode.*

FDA Label Image

4 (Carvedilol Phosphate 11)

Label for Carvedilol Phosphate Extended-Release Capsules, 80 mg strength, with a quantity of 30 capsules. The product is labeled for once-a-day dosing and is manufactured by Amneal Pharmaceuticals Pvt. Ltd. The label includes storage instructions and warnings about the safety seal and accidental overdose. The capsules are white with imprint H34. Distributed by Amneal Pharmaceuticals LLC.*

FDA Label Image

1 (Carvedilol Phosphate 2)

A line graph depicting mortality percentage over time in months comparing Carvedilol phosphate extended release capsules to placebo. The y-axis represents % mortality and the x-axis represents months from 0 to 21. Two lines show lower mortality with Carvedilol versus placebo, with a p-value of 0.0014 indicated.*

FDA Label Image

1 (Carvedilol Phosphate 3)

A forest plot showing hazard ratios with confidence intervals for various patient subgroups, including gender, age, race, diabetic status, ischemic condition, heart rate, systolic blood pressure, and spironolactone use, along with an overall measure for all patients. The plot depicts risk comparisons with a vertical line at hazard ratio 1.0 for reference.*

FDA Label Image

1 (Carvedilol Phosphate 4)

A line graph depicting percent mortality over 24 months comparing Carvedilol and Placebo groups. The y-axis represents percent mortality from 0 to 30%, and the x-axis shows time in months from 0 to 24. Two lines illustrate mortality trends, with Carvedilol showing consistently lower mortality than Placebo. A P-value of 0.03 is indicated on the chart.*

FDA Label Image

1 (Carvedilol Phosphate 5)

A forest plot chart depicting hazard ratios for various patient subgroups including age, sex, timing post-myocardial infarction, prior use of intravenous or oral beta blockers, Killip class, thrombolytic therapy, PTCA for MI, presence of congestive heart failure, diuretics use during MI, angina, hypertension, diabetes, heart rate, and systolic blood pressure. Each subgroup is represented with hazard ratio points and confidence intervals along a horizontal axis ranging from 0.4 to 1.3.*

FDA Label Image

1 (Carvedilol Phosphate 6)

A line graph showing the change in systolic blood pressure (SBP) over 24 hours after a morning dose of carvedilol phosphate extended-release capsules at strengths of 20 mg, 40 mg, and 80 mg. The x-axis represents time in hours, and the y-axis represents the change in SBP in mmHg. The graph compares the blood pressure reduction profiles of the three dosages over the time period.*

FDA Label Image

1 (Carvedilol Phosphate 7)

A line graph illustrating the change in diastolic blood pressure (DBP) in mmHg over 24 hours following a morning dose of carvedilol phosphate extended-release capsules at strengths of 20 mg, 40 mg, and 80 mg. The time in hours is shown on the x-axis, and change in DBP is shown on the y-axis.*

FDA Label Image

1 (Carvedilol Phosphate 8)

Label for Carvedilol Phosphate Extended-Release Capsules, 10 mg strength, oral dosage form. The label indicates a 30-capsule pack manufactured by Amneal Pharmaceuticals Pvt. Ltd. and distributed by Amneal Pharmaceuticals LLC. It includes usage instructions, storage conditions, and safety warnings, along with the NDC 0115-1248-08 and the Amneal logo.*

FDA Label Image

2 (Carvedilol Phosphate 9)

Label for Carvedilol Phosphate Extended-Release Capsules, 20 mg strength, oral capsules in a 30-count package. The label states once-a-day dosing, prescription use only, and includes storage and safety instructions. Manufactured by Amneal Pharmaceuticals Pvt. Ltd. and distributed by Amneal Pharmaceuticals LLC.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.